Lineage Cell Therapeutics (LCTX) Misses Q1 EPS by 2c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $3.43 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• ExxonMobil awards $1.1 billion in contracts for Mozambique LNG
• argenx SE (ARGX) PT Raised to $1,115 at Leerink